Amedeo Smart

Free Medical Literature Service

 

Amedeo

Liver Diseases
  Free Subscription

Articles published in
J Gastroenterol
    April 2026
  1. SHI F, Peng Z, Lian S, Mai Q, et al
    Lenvatinib plus hepatic arterial infusion chemotherapy of oxaliplatin, fluorouracil, and leucovorin versus lenvatinib alone for advanced hepatocellular carcinoma: a multicenter retrospective cohort study.
    J Gastroenterol. 2026 Apr 10. doi: 10.1007/s00535-026-02406.
    >> Share

  2. KUMADA T, Toyoda H, Ogawa S, Gotoh T, et al
    Comparative diagnostic performance of ultrasound-guided attenuation parameter versus B-mode scoring for hepatic steatosis assessment: an ordinal-scale statistical approach.
    J Gastroenterol. 2026 Apr 2. doi: 10.1007/s00535-026-02403.
    >> Share

  3. REN X, Yan C, Liu X, Jia X, et al
    Bifidobacterium bifidum CIP-01 attenuates metabolic dysfunction-associated steatotic liver disease induced by high-alcohol-producing Klebsiella pneumoniae.
    J Gastroenterol. 2026;61:462-476.
    >> Share

    March 2026
  4. ONO A, Miura R, Hayes CN, Kawaoka T, et al
    Reply to "IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma".
    J Gastroenterol. 2026 Mar 25. doi: 10.1007/s00535-026-02390.
    >> Share

  5. ZHANG F, Wang YS, Liu LX, Wang JZ, et al
    Reply to "Checking the shape of hepatocellular carcinoma: How irregular is irregular?".
    J Gastroenterol. 2026 Mar 21. doi: 10.1007/s00535-026-02394.
    >> Share

    February 2026
  6. SUN X, Zhang Y, Zhang X, Qin Q, et al
    Hepatocyte-specific yes-associated protein knockout exacerbates non-alcoholic steatohepatitis by upregulating PCSK9.
    J Gastroenterol. 2026 Feb 27. doi: 10.1007/s00535-026-02372.
    >> Share

  7. LIU J, Jia T
    Letter to the editor to ''Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis''.
    J Gastroenterol. 2026 Feb 24. doi: 10.1007/s00535-026-02375.
    >> Share

  8. ADNAN M, Khan S, Thasleem H, Imran J, et al
    IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2026 Feb 21. doi: 10.1007/s00535-026-02360.
    >> Share

  9. HUO TI, Ho SY
    Checking the shape of hepatocellular carcinoma: how irregular is irregular?
    J Gastroenterol. 2026 Feb 8. doi: 10.1007/s00535-026-02359.
    >> Share

  10. IMAOKA K, Ohira M, Yano T, Bekki T, et al
    Intestinal obstruction impairs the antitumor function of hepatic natural killer cells against colorectal cancer.
    J Gastroenterol. 2026 Feb 6. doi: 10.1007/s00535-026-02349.
    >> Share

  11. MYOJIN Y, Hikita H
    Growth differentiation factor 15: from stress response to clinical utility in chronic liver diseases.
    J Gastroenterol. 2026;61:117-130.
    >> Share

    January 2026
  12. SHEN L, Lv T, Li S, Chen S, et al
    Factors associated with recompensation and criteria for etiological suppression in patients with primary biliary cholangitis.
    J Gastroenterol. 2026 Jan 13. doi: 10.1007/s00535-025-02342.
    >> Share

    December 2025
  13. REN B, Li H, Liu S, Huang Z, et al
    Hic-5 deficiency attenuates MAFLD by inhibiting neutrophils migration via the CXCL1-CXCR2 axis.
    J Gastroenterol. 2025;60:1535-1553.
    >> Share

  14. TSURUSAKI M, Sofue K, Murakami T, Tanigawa N, et al
    Evidence for imaging-based diagnosis of liver metastases from colorectal cancer.
    J Gastroenterol. 2025;60:1471-1480.
    >> Share

    November 2025
  15. INADA H, Kurano S, Miyamoto H, Onishi M, et al
    TP53 mutation predicts resistance to immune checkpoint inhibitor-based therapy in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2025 Nov 17. doi: 10.1007/s00535-025-02320.
    >> Share

  16. ZHOU LX, He CH, Dong H, Gao TM, et al
    Validation of Baveno VII criteria for recompensation in patients with decompensated cirrhosis treated by laparoscopic splenectomy and azygoportal disconnection.
    J Gastroenterol. 2025 Nov 8. doi: 10.1007/s00535-025-02317.
    >> Share

  17. HINO K, Nishina S, Yanatori I
    Ferroptosis: biology and role in liver disease.
    J Gastroenterol. 2025;60:1339-1361.
    >> Share

  18. TAKEMURA Y, Ueda Y, Takemura R, Mita J, et al
    Current status of waitlist mortality and transplant probability for adult candidates with chronic end-stage liver disease for deceased donor liver transplantation under the Model for End-Stage Liver Disease score-based allocation policy in Japan.
    J Gastroenterol. 2025;60:1414-1426.
    >> Share

    October 2025
  19. TAHATA Y, Hikita H, Takaki A, Kurosaki M, et al
    Long-term changes in hepatic reserve and prognosis after direct-acting antiviral treatment in patients with hepatitis C virus-related decompensated cirrhosis: a five-year follow-up study of a Japanese phase 3 trial.
    J Gastroenterol. 2025 Oct 30. doi: 10.1007/s00535-025-02312.
    >> Share

  20. MAESAKA K, Hikita H, Tahata Y, Nishioka C, et al
    Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Oct 25. doi: 10.1007/s00535-025-02308.
    >> Share

  21. IWASA T, Miwa T, Utakata Y, Oi M, et al
    Development of overt hepatic encephalopathy increases mortality in patients with cirrhosis: a multicenter retrospective cohort study.
    J Gastroenterol. 2025 Oct 17. doi: 10.1007/s00535-025-02309.
    >> Share

  22. NAKADAI Y, Ojiro K, Kasuga R, Chu PS, et al
    Validation of novel scoring systems for acute decompensated cirrhosis identifies PBC as an independent poor prognostic factor: a single-center Japanese cohort study.
    J Gastroenterol. 2025 Oct 12. doi: 10.1007/s00535-025-02310.
    >> Share

  23. MIYAKE T, Yoshida O, Furukawa S, Sato Y, et al
    GPAM upregulation enhances hepatic fat deposition and reduces visceral adipose tissue in response to trans-fatty acids.
    J Gastroenterol. 2025 Oct 4. doi: 10.1007/s00535-025-02297.
    >> Share

  24. FUJII H, Uchida-Kobayashi S, Kanamori A, Nadatani Y, et al
    Defining optimal fatty liver index thresholds for MASLD and MetALD using controlled attenuation parameter as reference.
    J Gastroenterol. 2025;60:1296-1309.
    >> Share

  25. LEE J, Cha JH, Cho HS, Yang K, et al
    The PNPLA3 I148M variant is associated with immune cell infiltration and advanced fibrosis in MASLD: a prospective genotype-phenotype study.
    J Gastroenterol. 2025;60:1284-1295.
    >> Share

    August 2025
  26. OHAMA H, Hiraoka A, Tada T, Hirooka M, et al
    Potential role of Geriatric Nutritional Risk Index as a risk factor for immune-mediated adverse events during durvalumab plus tremelimumab therapy in unresectable hepatocellular carcinoma.
    J Gastroenterol. 2025 Aug 20. doi: 10.1007/s00535-025-02290.
    >> Share

  27. KIDO H, Mizukoshi E, Yanagi M, Shihui L, et al
    Abnormalities of intracellular organelles in metabolic dysfunction-associated steatotic disease.
    J Gastroenterol. 2025;60:990-999.
    >> Share

    July 2025
  28. YAMASAKI S, Nakahara T, Tsuge M, Yamaoka K, et al
    Metabolic dysfunction-associated steatotic liver disease affects the development of hepatocellular carcinoma after sustained virologic response in chronic hepatitis C patients.
    J Gastroenterol. 2025 Jul 7. doi: 10.1007/s00535-025-02270.
    >> Share

  29. TSUTSUMI T, Kawaguchi T, Fujii H, Kamada Y, et al
    Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis.
    J Gastroenterol. 2025;60:891-904.
    >> Share

  30. SUZUKI T, Matsuura K, Tahata Y, Hikita H, et al
    Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy.
    J Gastroenterol. 2025 Jul 1. doi: 10.1007/s00535-025-02282.
    >> Share

    June 2025
  31. OFUCHI T, Otsu H, Hosoda K, Ikehara T, et al
    VPS45 promotes the progression of hepatocellular carcinoma by recycling beta1 integrin to the cell membrane via the endocytic pathway.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02278.
    >> Share

  32. KAWAGISHI N, Suda G, Tahata Y, Hikita H, et al
    Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis.
    J Gastroenterol. 2025 Jun 20. doi: 10.1007/s00535-025-02275.
    >> Share

  33. LIU WM, Chen CY, Ma HQ, Zhang QQ, et al
    Inhibition of liver cancer cell growth by metabolites S-adenosylmethionine and nicotinic acid originating from liver progenitor cells.
    J Gastroenterol. 2025;60:754-769.
    >> Share

    May 2025
  34. ONO A, Hayes CN, Miura R, Kawaoka T, et al
    Noninvasive prediction of the clinical benefit of immunotherapy in hepatocellular carcinoma.
    J Gastroenterol. 2025 May 30. doi: 10.1007/s00535-025-02251.
    >> Share

  35. DING H, Lv H, Sui M, Wang X, et al
    Interaction of neuropilin-1 and hepatocyte growth factor/C-Met pathway in liver fibrosis progression in hepatocyte-specific NRP-1 knockout mice.
    J Gastroenterol. 2025 May 26. doi: 10.1007/s00535-025-02262.
    >> Share

  36. XIA M, Lu Y, Yin F, Cao Z, et al
    The external validation of Dallas Steatosis Index among Asian population: a useful tool for metabolic dysfunction-associated steatotic liver disease identification and prevention.
    J Gastroenterol. 2025;60:621-631.
    >> Share

    April 2025
  37. ZHANG Y, Che N, Wang S, Meng J, et al
    Correction: Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2025 Apr 23. doi: 10.1007/s00535-025-02246.
    >> Share

  38. OURA K, Morishita A, Yano R, Manabe T, et al
    Circulating miR-485-3p as a biomarker for VEGF-associated therapeutic response to atezolizumab plus bevacizumab in hepatocellular carcinoma.
    J Gastroenterol. 2025 Apr 3. doi: 10.1007/s00535-025-02239.
    >> Share

  39. HANAMATSU H, Suda G, Ohara M, Ogawa K, et al
    Elevated A2F bisect N-glycans of serum IgA reflect progression of liver fibrosis in patients with MASLD.
    J Gastroenterol. 2025;60:456-468.
    >> Share

    March 2025
  40. MIWA T, Tsuruoka M, Ueda H, Abe T, et al
    Current management and future perspectives of covert hepatic encephalopathy in Japan: a nationwide survey.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02232.
    >> Share

  41. AOKI T, Kudo M, Nishida N, Ueshima K, et al
    Proposal of discontinuation criteria of atezolizumab plus bevacizumab after curative conversion therapy for unresectable early-to-intermediate-stage hepatocellular carcinoma: a multicenter proof-of-concept study.
    J Gastroenterol. 2025 Mar 7. doi: 10.1007/s00535-025-02233.
    >> Share

  42. DU T, Huang Y, Lv Y, Yuan G, et al
    Liver fibrotic burden across the spectrum of hypothyroidism.
    J Gastroenterol. 2025;60:315-327.
    >> Share

  43. WANG H, Liu Z, Fan H, Guo C, et al
    Association between advanced fibrosis and epigenetic age acceleration among individuals with MASLD.
    J Gastroenterol. 2025;60:306-314.
    >> Share

    February 2025
  44. NISHIMURA T, Tada T, Akita T, Kondo R, et al
    Diagnostic performance of attenuation imaging versus controlled attenuation parameter for hepatic steatosis with MRI-based proton density fat fraction as the reference standard: a prospective multicenter study.
    J Gastroenterol. 2025 Feb 24. doi: 10.1007/s00535-025-02224.
    >> Share

  45. TANAKA A, Notohara K, Tobari M, Abe M, et al
    A clinicopathological study of IgG4-related autoimmune hepatitis and IgG4-hepatopathy.
    J Gastroenterol. 2025 Feb 8. doi: 10.1007/s00535-025-02221.
    >> Share

  46. KOGISO T, Ogasawara Y, Taniai M, Shimada E, et al
    Impact of ursodeoxycholic acid treatment on Fontan-associated liver disease.
    J Gastroenterol. 2025;60:210-221.
    >> Share

  47. KURODA H, Abe T, Kamiyama N, Oguri T, et al
    Novel subharmonic-aided pressure estimation for identifying high-risk esophagogastric varices.
    J Gastroenterol. 2025;60:187-196.
    >> Share

    January 2025
  48. WEN C, Tao H, Chen H, Pu W, et al
    Single-cell RNA sequencing and functional analysis reveal the role of altered glycosylation levels of hepatic macrophages in liver cirrhosis.
    J Gastroenterol. 2025 Jan 31. doi: 10.1007/s00535-025-02218.
    >> Share

  49. ZHANG X, Li J, Yao Y, Zhou M, et al
    Migrasome-related prognostic signature TSPAN4 correlates with immune infiltrates and metabolic disturbances in hepatocellular carcinoma.
    J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212.
    >> Share

  50. KASAI Y, Ito T, Masui T, Nagai K, et al
    Liver transplantation for gastroenteropancreatic neuroendocrine liver metastasis: optimal patient selection and perioperative management in the era of multimodal treatments.
    J Gastroenterol. 2025;60:1-9.
    >> Share

    December 2024
  51. ZHANG F, Wang YS, Li SP, Zhao B, et al
    Alpha-fetoprotein combined with initial tumor shape irregularity in predicting the survival of patients with advanced hepatocellular carcinoma treated with immune-checkpoint inhibitors: a retrospective multi-center cohort study.
    J Gastroenterol. 2024 Dec 23. doi: 10.1007/s00535-024-02202.
    >> Share

  52. MIURA R, Ono A, Nakahara H, Shirane Y, et al
    Serum IL-6 concentration is a useful biomarker to predict the efficacy of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02185.
    >> Share

  53. KAMADA Y, Sumida Y, Takahashi H, Fujii H, et al
    Utility of Mac-2 binding protein glycosylation isomer as an excellent biomarker for the prediction of liver fibrosis, activity, and hepatocellular carcinoma onset: an expert review.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02179.
    >> Share

  54. IMAI Y, Koizumi Y, Hiasa Y, Hirooka M, et al
    Standard technique in Japan for measuring hepatic venous pressure gradient.
    J Gastroenterol. 2024 Dec 9. doi: 10.1007/s00535-024-02182.
    >> Share

  55. RABIU L, Zhang P, Afolabi LO, Saliu MA, et al
    Immunological dynamics in MASH: from landscape analysis to therapeutic intervention.
    J Gastroenterol. 2024;59:1053-1078.
    >> Share

    November 2024
  56. CAO Z, Yang Y, Liu S, Sun L, et al
    FGFR2 fusions assessed by NGS, FISH, and immunohistochemistry in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Nov 13. doi: 10.1007/s00535-024-02175.
    >> Share

    October 2024
  57. LIU WJ, Wu WJ, Lin CL, Liu CJ, et al
    Impact of age at HBsAg seroclearance on hepatic outcomes and life expectancy in men with chronic HBV infection based on multi-state modeling of the natural history.
    J Gastroenterol. 2024 Oct 22. doi: 10.1007/s00535-024-02162.
    >> Share

  58. UENO M, Takeda H, Takai A, Morimura H, et al
    Publisher Correction: CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Oct 21. doi: 10.1007/s00535-024-02159.
    >> Share

  59. SOMA N, Uchida Y, Kouyama JI, Naiki K, et al
    Serum zinc levels as predictors of covert hepatic encephalopathy in patients with liver cirrhosis.
    J Gastroenterol. 2024 Oct 16. doi: 10.1007/s00535-024-02160.
    >> Share

  60. KAWAGUCHI T, Fujishima Y, Wakasugi D, Io F, et al
    Effects of SGLT2 inhibitors on the onset of esophageal varices and extrahepatic cancer in type 2 diabetic patients with suspected MASLD: a nationwide database study in Japan.
    J Gastroenterol. 2024 Oct 11. doi: 10.1007/s00535-024-02158.
    >> Share

  61. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Response to letter to the editor regarding: "Alcohol-associated liver disease increases the risk of muscle reduction and mortality in patients with cirrhosis".
    J Gastroenterol. 2024 Oct 4. doi: 10.1007/s00535-024-02153.
    >> Share

  62. SANCHEZ-MONTEAGUDO A, Ripolles E, Murillo O, Domenech S, et al
    Profile of plasma microRNAs as a potential biomarker of Wilson's disease.
    J Gastroenterol. 2024;59:921-931.
    >> Share

    September 2024
  63. KUNZLER IL, Da Croce MA, Fornari F
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Sep 23. doi: 10.1007/s00535-024-02154.
    >> Share

  64. UENO M, Takeda H, Takai A, Morimura H, et al
    CRAFITY score as a predictive marker for refractoriness to atezolizumab plus bevacizumab therapy in hepatocellular carcinoma: a multicenter retrospective study.
    J Gastroenterol. 2024 Sep 18. doi: 10.1007/s00535-024-02150.
    >> Share

  65. YAMAUCHI K, Maekawa S, Osawa L, Komiyama Y, et al
    Single-molecule sequencing of the whole HCV genome revealed envelope deletions in decompensated cirrhosis associated with NS2 and NS5A mutations.
    J Gastroenterol. 2024 Sep 3. doi: 10.1007/s00535-024-02146.
    >> Share

  66. KAWAGUCHI T, Murotani K, Kajiyama H, Obara H, et al
    Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials.
    J Gastroenterol. 2024;59:836-848.
    >> Share

    August 2024
  67. YU C, Tang Y, Liu M, Xu X, et al
    The risk stratification and predictive performance of a new combined polygenic risk score for hepatocellular carcinoma.
    J Gastroenterol. 2024 Aug 10. doi: 10.1007/s00535-024-02144.
    >> Share

  68. ZHANG Y, Che N, Wang S, Meng J, et al
    Nrf2/ASPM axis regulated vasculogenic mimicry formation in hepatocellular carcinoma under hypoxia.
    J Gastroenterol. 2024 Aug 3. doi: 10.1007/s00535-024-02140.
    >> Share

    July 2024
  69. HANAI T, Nishimura K, Unome S, Miwa T, et al
    Alcohol-associated liver disease increases the risk of muscle loss and mortality in patients with cirrhosis.
    J Gastroenterol. 2024 Jul 28. doi: 10.1007/s00535-024-02137.
    >> Share

  70. HAO Y, Hao Z, Zeng X, Lin Y, et al
    Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    J Gastroenterol. 2024 Jul 19. doi: 10.1007/s00535-024-02134.
    >> Share

  71. AMPUERO J, Aller R, Gallego-Duran R, Crespo J, et al
    The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
    J Gastroenterol. 2024;59:586-597.
    >> Share

    June 2024
  72. MIWA T, Utakata Y, Hanai T, Aiba M, et al
    Acute kidney injury development is associated with mortality in Japanese patients with cirrhosis: impact of amino acid imbalance.
    J Gastroenterol. 2024 Jun 11. doi: 10.1007/s00535-024-02126.
    >> Share

  73. WAKABAYASHI SI, Tamaki N, Kimura T, Umemura T, et al
    Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease.
    J Gastroenterol. 2024;59:494-503.
    >> Share

  74. HIROOKA M, Ogawa S, Koizumi Y, Yoshida Y, et al
    iATT liver fat quantification for steatosis grading by referring to MRI proton density fat fraction: a multicenter study.
    J Gastroenterol. 2024;59:504-514.
    >> Share

  75. MINO M, Sano A, Kakazu E, Matsubara H, et al
    Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.
    J Gastroenterol. 2024;59:483-493.
    >> Share

    May 2024
  76. ATSUKAWA M, Tsubota A, Kondo C, Toyoda H, et al
    ALBI score predicts morphological changes in esophageal varices following direct-acting antiviral-induced sustained virological response in patients with liver cirrhosis.
    J Gastroenterol. 2024 May 10. doi: 10.1007/s00535-024-02109.
    >> Share

    April 2024
  77. FUJIWARA K, Kondo T, Fujimoto K, Yumita S, et al
    Clinical risk factors for portal hypertension-related complications in systemic therapy for hepatocellular carcinoma.
    J Gastroenterol. 2024 Apr 7. doi: 10.1007/s00535-024-02097.
    >> Share

  78. CORNEJO-PAREJA I, Amiar MR, Ocana-Wilhelmi L, Soler-Humanes R, et al
    Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
    J Gastroenterol. 2024;59:329-341.
    >> Share

    March 2024
  79. XIN HY, Zou JX, Sun RQ, Hu ZQ, et al
    Characterization of tumor microbiome and associations with prognosis in intrahepatic cholangiocarcinoma.
    J Gastroenterol. 2024 Mar 10. doi: 10.1007/s00535-024-02090.
    >> Share

  80. WANG J, Zhang H, Chen L, Fu K, et al
    CircDCBLD2 alleviates liver fibrosis by regulating ferroptosis via facilitating STUB1-mediated PARK7 ubiquitination degradation.
    J Gastroenterol. 2024;59:229-249.
    >> Share

    February 2024
  81. WU C, Li J, Jia H, Zhao J, et al
    Indoleamine 2,3-dioxygenase 1-mediated iron metabolism in macrophages contributes to lipid deposition in nonalcoholic steatohepatitis.
    J Gastroenterol. 2024 Feb 24. doi: 10.1007/s00535-024-02082.
    >> Share

  82. NAMISAKI T, Sato S, Yoshiji H
    Role of combined aerobic and resistance exercise in liver cirrhosis.
    J Gastroenterol. 2024 Feb 8. doi: 10.1007/s00535-024-02078.
    >> Share

    January 2024
  83. KOBAYASHI T, Iwaki M, Nogami A, Kawamura N, et al
    Prediction of outcomes in patients with metabolic dysfunction-associated steatotic liver disease based on initial measurements and subsequent changes in magnetic resonance elastography.
    J Gastroenterol. 2024;59:56-65.
    >> Share

  84. HANAI T, Nishimura K, Unome S, Miwa T, et al
    A survey questionnaire evaluating physical activity patterns and determinants in patients with chronic liver disease.
    J Gastroenterol. 2024;59:45-55.
    >> Share

    December 2023
  85. KAWAGUCHI T, Kawaguchi A, Hashida R, Nakano D, et al
    Resistance exercise in combination with aerobic exercise reduces the incidence of serious events in patients with liver cirrhosis: a meta-analysis of randomized controlled trials.
    J Gastroenterol. 2023 Dec 30. doi: 10.1007/s00535-023-02060.
    >> Share

  86. ICHITA C, Goto T, Shimizu S
    Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data.
    J Gastroenterol. 2023 Dec 19. doi: 10.1007/s00535-023-02066.
    >> Share

  87. UENO M, Fujiwara T, Tokumasu H, Mizuno M, et al
    Reply to "Considerations for evaluating antibiotic prophylaxis in cirrhotic patients with upper gastrointestinal bleeding in real-world data".
    J Gastroenterol. 2023 Dec 13. doi: 10.1007/s00535-023-02067.
    >> Share

    November 2023
  88. YANG Z, Shi M, Liang Y, Zhang F, et al
    Three-dimensional chromatin landscapes in hepatocellular carcinoma associated with hepatitis B virus.
    J Gastroenterol. 2023 Nov 5. doi: 10.1007/s00535-023-02053.
    >> Share

  89. TADA F, Hiraoka A, Tada T, Hirooka M, et al
    Efficacy and safety of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients with esophageal-gastric varices.
    J Gastroenterol. 2023;58:1134-1143.
    >> Share

    October 2023
  90. WANG H, Li Y, Pu X, Liang X, et al
    MGAT5/TMEM163 variant is associated with prognosis in ursodeoxycholic acid-treated patients with primary biliary cholangitis.
    J Gastroenterol. 2023 Oct 16. doi: 10.1007/s00535-023-02045.
    >> Share

  91. TAHATA Y, Hikita H, Mochida S, Enomoto N, et al
    Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
    J Gastroenterol. 2023 Oct 13. doi: 10.1007/s00535-023-02039.
    >> Share

  92. CRANE H, Gofton C, Sharma A, George J, et al
    MAFLD: an optimal framework for understanding liver cancer phenotypes.
    J Gastroenterol. 2023;58:947-964.
    >> Share

    September 2023
  93. KADO A, Tsutsumi T, Yotsuyanagi H, Ikeuchi K, et al
    Noninvasive approach to indicate risk factors of nonalcoholic steatohepatitis overlapping autoimmune hepatitis based on peripheral lymphocyte pattern.
    J Gastroenterol. 2023 Sep 14. doi: 10.1007/s00535-023-02038.
    >> Share

  94. WEI M, Chen Y, Wang M, Li J, et al
    Correction: Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02036.
    >> Share

  95. OZONO Y, Kawakami H, Uchiyama N, Hatada H, et al
    Current status and issues in genomic analysis using EUS-FNA/FNB specimens in hepatobiliary-pancreatic cancers.
    J Gastroenterol. 2023 Sep 12. doi: 10.1007/s00535-023-02037.
    >> Share

  96. LIU C, Zhu S, Zhang J, Wu P, et al
    Global, regional, and national burden of liver cancer due to non-alcoholic steatohepatitis, 1990-2019: a decomposition and age-period-cohort analysis.
    J Gastroenterol. 2023 Sep 4. doi: 10.1007/s00535-023-02040.
    >> Share

    July 2023
  97. WEI M, Chen Y, Wang M, Li J, et al
    Partial splenic embolization combined with endoscopic therapies and vasoconstrictive drugs reduces rebleeding in cirrhosis patients with acute variceal bleeding and hypersplenism: a multicenter randomized controlled trial.
    J Gastroenterol. 2023 Jul 24. doi: 10.1007/s00535-023-02027.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016